References
DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. Blood. 2007;109:5136–42.
Gokbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504–11.
Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995–9.
Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104:e100–e3.
Ganzel C, Kharit M, Duksin C, Rowe JM. Daratumumab for relapsed/refractory philadelphia-positive acute lymphoblastic leukemia. Haematologica. 2018;103:e489–e90.
Bonda A, Punatar S, Gokarn A, Mohite A, Shanmugam K, Nayak L, et al. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy? Bone Marrow Transpl. 2018;53:1487–9.
Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–94.
Klyuchnikov E, von Pein U-M, Ayuk FA, Christopeit M, Adjalle R, van Randenborgh A, et al. Daratumumab is an effective and safe salvage therapy in relapsed/refractory patients with multiple myeloma after allogeneic stem cell transplantation. Blood. 2016;128:3437.
Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379:1846–50.
Acknowledgements
We would like to gratefully acknowledge the assistance of Sonia Kamenetsky in the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
YO: designed research, interpreted data, wrote the paper, approved its final version. SR-H, IS, TZ, DY-O, IH, OB-K, MH, and AF: performed research, approved its final version of the paper.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ofran, Y., Ringelstein-Harlev, S., Slouzkey, I. et al. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia 34, 293–295 (2020). https://doi.org/10.1038/s41375-019-0548-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0548-z
- Springer Nature Limited
This article is cited by
-
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
Annals of Hematology (2024)
-
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
Experimental Hematology & Oncology (2023)
-
Daratumumab—a novel treatment strategy in relapsed/refractory acute leukemia
Annals of Hematology (2023)
-
Lymphoblastic Lymphoma: a Concise Review
Current Oncology Reports (2022)
-
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
Biomarker Research (2021)